Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Immutep (IMM AU)
Watchlist
23
Analysis
Health Care
•
Australia
Immutep Limited operates as a biotechnology company. The Company focuses on developing novel immunotherapy treatments for cancer and autoimmune disease. Immutep offers its services worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Immutep
•
23 Mar 2017 19:26
•
Issuer-paid
Initial LAG-3 combo data presented
Prima BioMed has presented encouraging early signs of efficacy from the TACTI-mel trial of IMP321 in combination with Keytruda, with one of the six...
Edison Investment Research
Follow
67 Views
Share
bullish
•
Immutep
•
22 Mar 2017 19:53
•
Issuer-paid
Initial LAG-3 combo data presented
Prima BioMed has presented encouraging early signs of efficacy from the TACTI-mel trial of IMP321 in combination with Keytruda, with one of the six...
Edison Investment Research
Follow
55 Views
Share
bullish
•
Immutep
•
16 Feb 2017 21:03
•
Issuer-paid
AIPAC Phase IIb starts randomized component
Prima BioMed maintains its leadership in LAG-3 immunotherapies with the initiation of the randomized Phase IIb component of the AIPAC trial of...
Edison Investment Research
Follow
61 Views
Share
bullish
•
Immutep
•
16 Feb 2017 03:00
•
Issuer-paid
AIPAC Phase IIb starts randomised component
Prima BioMed maintains its leadership in LAG-3 immunotherapies with the initiation of the randomised Phase IIb component of the AIPAC trial of...
Edison Investment Research
Follow
60 Views
Share
First
Previous
1
2
3
4
5
Next
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.36.0
x